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ABSTRACT
Analysis of Anti-Retroviral Procurement for HIV-Affected Countries from Fiscal Years
2012 to 2014

Dejené Marshall
8/16/2016
BACKGROUND:
In 2015, the World Health Organization expanded eligibility for anti-retroviral
therapy (ART) to all individuals affected with HIV, regardless of CD4 count. Although, antiretroviral drugs (ARVs) are essential to HIV/AIDS treatment and therapy, ARVs may also
pose a financial burden on low-income countries affected by a high prevalence of HIV.
Programs funded by global donor organizations such as the President’s Emergency Plan for
AIDS Relief (PEPFAR) may provide assistance to these HIV-affected populations through
the procurement of ARVs. The objective of this analysis was to determine total ARV
expenditures for SCMS participating countries from fiscal years 2012 to 2014 and to
discuss the implications of generic ARV procurement under the WHO and UNAIDS
guidelines.
METHODS:
The SCMS Delivery History Dataset was used to determine the number of purchase
orders for generic and brand name ARVs, as well as calculate the expenditures for overall,
brand name and generic ARVS for 2012-2014.
RESULTS:
From 2012 to 2013, the procurement of overall and generic ARVs increased,
however, from 2013 to 2014, there was a decrease in generic and overall ARV
procurement. The number of brand name ARV transactions increased during this three
year period from 78 in FY 2012, 144 in FY 2013, and 164 in FY 2014 respectively. The antiretroviral drug Keletra was the most frequently purchased ARV in FY 2012 and FY 2014. In
FY 2013, the most frequently purchased ARV was Aluvia.
DISCUSSION:
It is recommended that the international public health community continues to
develop more cost-effective methods of procuring ARVs to resource-limited, HIV-affected
populations. Although there are barriers to obtaining generic formulations for antiretrovirals, there are possible consequences of low uptake of generic ARV procurement. If a
country is unable to efficiently secure enough ARVs for HIV-affected individuals, it is more
unlikely that HIV/AIDS will be eliminated in that location within the next several years,
according to the UNAIDS and WHO recommendations.
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Chapter I
INTRODUCTION
1.1 Background
In 2015, although 36.7 million people were living with HIV/AIDS globally, only 17
million of those infected with the virus were able to access and undergo anti-retroviral
therapy (ART) (UNAIDS, 2016). Two-thirds of those infected resided in Sub-Saharan Africa
(PEPFAR, 2016). UNAIDS suggests that approximately 26.2 billion US dollars will be
needed for the HIV/AIDS response in 2020 and approximately 23.9 billion US dollars in
2030 (2016).
Several international organizations have implemented programs and initiatives to
address the HIV epidemic. One of the major unifying goals between these organizations are
the 90-90-90 targets developed in 2014 by Joint United Nations Programme on HIV/AIDS,
known as UNAIDS. The 90-90-90 targets include the following: 90% of HIV-positive
individuals will know their status, 90% of HIV-positive individuals will have sufficient ART
and 90% of those on ART will have viral suppression (UNAIDS, 2014). UNAIDS suggests
that meeting the 90-90-90 targets by 2020 will result in the end of the AIDS epidemic by
2030, while acknowledging this is an ambitious goal (UNAIDS, 2014).
One year later in 2015, the World Health Organization (WHO) published guidelines
that recommended universal ART for adults, adolescents and children who are HIV positive
regardless their CD4 count (WHO, 2015). This guideline dramatically increased the number
of individuals who may need ART and inspired countries throughout the world to revisit
their national guidelines to meet these new WHO recommendations.

1

The President’s Emergency Plan for AIDS Relief, known as PEPFAR, is the U.S.
government initiative to globally combat the HIV/AIDS epidemic (PEPFAR n.d.). In 2008,
PEPFAR was expanded under the Tom Lantos and Henry J. Hyde United States Global
Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008,
which authorized 48 billion US dollars towards this multi-year HIV/AIDS strategy
(PEPFAR, n.d.). Since the launch of PEPFAR until Fiscal Year (FY) 2013, there has been over
52 billion US dollars committed to various international HIV/AIDS, tuberculosis and
malaria programs across 54 countries (PEPFAR, n.d.). PEPFAR 3.0 has allocated
approximately 5.2 million US dollars to bi-lateral HIV/AIDS programs so far in 2016 alone
(PEPFAR, 2016). Since PEPFAR funds are appropriated through Congress, there are
accountability measures that must be taken to ensure the proper allocation of funding.
The Office of the US Global AIDS Coordinator, also known as OGAC, manages the
entire PEPFAR program and PEPFAR funding. Additionally, OGAC approves all PEPFAR
activities and funding that is allocated to a country or region. In order for a country to
receive assistance, their government must work with OGAC to develop a Partnership
Framework. Partnership Frameworks detail a 5-year plan between the specific HIVaffected country, the United States Government, and other partners to eliminate HIV/AIDS
through coordinated financial contributions and service delivery. Then, the host country
must develop a Country Operational Plan, which vastly details the use of all sources of U.S.
appropriated funds for each fiscal year, along with several other quarterly and annual
reports from each PEPFAR site. OGAC reports this information back to Congress on a
quarterly basis.
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The Supply Chain Management System, also known as the SCMS, was established in
2005 under PEPFAR and United States Agency for International Development (USAID) to
procure HIV/AIDS supplies to partnering countries (SCMS, n.d.). Since then, over 2.6 billion
US dollars’ worth of essential commodities have been delivered, particularly for antiretroviral drugs (ARVs), which dramatically increased accessibility to many HIV-affected
countries (SCMS, n.d.). Currently, SCMS provides 70 percent of all ARVs that are funded by
PEPFAR (SCMS, n.d.).

1.2. Purpose
WHO and UNAIDS’ ambitious goals to eliminate HIV/AIDS reinforce the importance
of anti-retroviral treatment (ART) for HIV-affected individuals across the globe. Reaching
these objectives requires an increase in delivery of anti-retrovirals (ARVs) to a larger
concentration of people. Consequentially, an increase of international ARV funding and
procurement to resource-limited settings requires a closer look at the global supply chain
system to ensure that the expenses are appropriately spent and the outcomes are
maximized. The purpose of this analysis is to review international ARV expenditures and
discuss the implications of generic ARV scale-up for countries highly affected by HIV/AIDS.
The data collected will be useful to guide future policy decisions.
1.3. Research Questions
1. What are the total ARV expenditures (overall, generic and brand name) for a sample of
HIV-affected countries from fiscal years 2012 to 2014?
2. What are the implications of generic ARV procurement under the recent WHO and
UNAIDS recommendations?
3

Chapter II
REVIEW OF THE LITERATURE
In response to the WHO/UNAIDS recommendations, there will be a two-fold
increase in ARVs supplied worldwide to ensure that all 25 million HIV-affected individuals
are on treatment (Jamieson & Kellerman, 2016). An estimated 45.8 billion US dollars in
facility-level resources are also needed to scale up ART from 2015 to 2020 (Dutta, Barker
and Kallerakal, 2015). Based on these and other recent findings, it is important to review
previous studies for more cost-effective methods to scale-up ART worldwide. It has been
proposed that ARV prices must be reduced in order to ensure universal access to ART
(Vasan et al., 2006). Additionally, international drug tendering processes should be
negotiated between the partnering country government and the supplier before the
implementation phase to avoid delays and unnecessarily purchasing expensive ARVs
(Steyn et al., 2009). For example, South Africa escalated ART delivery in January 2005 but
due to an inconsistent flow of ARVs and incomplete drug tendering negotiations, many HIVaffected individuals died waiting on the first supply (Steyn et al., 2009).
A study from the Office of the US Global AIDS Coordinator found that by 2008, 90%
of the 22 million PEPFAR-sponsored ARV packs procured were generic (Holmes et al.,
2010). Generic ARVs are more cost-effective than brand name ARVs, especially when they
are procured through a global donor organization such as the Clinton HIV/AIDS Initiative
(CHAI) or the Global Fund (Waning et al., 2009). Additionally, through these international
organizations, the quality of the ARVs must meet the standards of the WHO Prequalification
Programme and the United States Federal Drug Administration (FDA) (Waning et al.,
2009). This aims to ensure that quality is not compromised by the price of the ARV.
4

Chapter III
METHODS
The SCMS Delivery History Dataset contains transactional information from the
distribution of HIV/AIDS supplies to PEPFAR-supported countries. USAID collects,
manages, and publishes the SCMS procurement data on an almost quarterly basis. The
SCMS Delivery History Dataset used in this analysis was published on the PEPFAR Data
Dashboard website in the first quarter of the 2016 fiscal year. This dataset was used to
calculate the expenditures for overall, brand name and generic ARVS for 2012-2014 and all
costs are recorded in US dollars. There were 33 total data fields included in the SCMS
Delivery History Dataset, however, only the following eight data fields were used for this
analysis: destination country, date of delivery to client, product group, item description,
line item value, pack price, unit price, and first line designation. It is worth noting that both
adult and pediatric formulations were considered, but the only product group measured
was ARV. The raw data collected were associated by calendar year, but for this analysis, the
delivery dates were grouped by fiscal year. Only the line item value and collective unit
prices were included in the dataset and in some cases, the line item contained more than
four drugs at a time. Therefore for this analysis, the aggregate totals were calculated in
Microsoft Excel. Lastly, there were 21 PEPFAR-supported countries that provided
expenditure information for the SCMS for 2012, and 19 countries in both 2013 and 2014.
The dataset was cleaned by removing entries that contained duplicates, blanks, null and
zeros. Microsoft Excel was used to generate PivotTables and charts. Since the data were
collected from a procurement system and not individuals, Institutional Review Board
approval was not a requirement.
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Chapter IV
RESULTS
Table 1: Total Generic ARV Expenditures
from High Burden Countries in FY 2012
Country
Angola
Burundi
Cameroon
Congo, DRC
Côte d'Ivoire
Dominican Republic
Guyana
Haiti
Malawi
Mozambique
Nigeria
Rwanda
South Africa
South Sudan
Tanzania
Uganda
Vietnam
Zambia
Zimbabwe
Total

Table 2: Total Generic ARV Expenditures
from High Burden Countries in FY 2013

ARV Expenditures
$6,806.40
$167,493.51
$6,297,229.33
$454,474.97
$10,284,116.10
$50,787.80
$159,026.12
$5,912,640.20
$5,745,000.00
$17,103,688.22
$41,698,164.61
$6,435,373.72
$1,029,267.29
$217,128.46
$17,449,741.06
$23,288,284.69
$8,055,755.10
$24,057,471.54
$18,162,235.57
$186,574,684.69

Country
Burundi
Cameroon
Congo, DRC
Côte d'Ivoire
Dominican Republic
Ethiopia
Ghana
Guyana
Haiti
Mozambique
Namibia
Nigeria
Rwanda
South Africa
South Sudan
Tanzania
Uganda
Vietnam
Zambia
Zimbabwe
Total
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ARV Expenditures
$236,728.03
$5,451,156.16
$1,036,139.04
$11,784,474.95
$622,758.46
$14,975.66
$2,865,796.85
$194,319.26
$2,481,226.20
$45,068,284.16
$1,091,981.73
$38,506,387.29
$10,709,618.45
$983,092.93
$117,420.34
$27,355,756.54
$14,006,450.26
$6,180,101.20
$31,945,622.57
$25,961,770.18
$226,614,060.26

Table 3: Total Generic ARV Expenditures
from PEPFAR-Supported Countries in FY
2014
Country
Botswana
Burkina Faso
Burundi
Cameroon
Congo, DRC
Côte d'Ivoire
Ghana
Guyana
Haiti
Mozambique
Namibia
Nigeria
Rwanda
Senegal
South Africa
South Sudan
Swaziland
Tanzania
Togo
Uganda
Vietnam
Zambia
Zimbabwe
Total

Based on the SCMS Delivery History
Dataset, PEPFAR-supported countries

ARV Expenditures
$1,109,720.71
$280.00
$355,857.97
$459,717.30
$1,602,386.02
$12,512,816.03
$2,348,550.74
$105,519.58
$12,766,271.17
$40,208,699.02
$2,531,325.26
$54,552,209.40
$9,780,723.70
$200.00
$502,464.76
$811,416.93
$649,350.00
$1,322,314.13
$153,781.24
$12,497,819.86
$7,537,796.65
$27,087,851.26
$22,477,140.19
$211,374,211.92

spent $186,574,684.69 on generic ARV
drugs in FY 2012, $226,614,060.26 in FY
2013, and $211,374,211.92 in FY 2014 as
shown in Tables 1, 2 and 3. Nigeria spent
$41,698,164.61 in FY 2012 and
$54,552,209.40 in FY 2014 on generic
ARVs, more than any other country
program observed, respectively. Similarly,
Mozambique spent the most funds on
generics ($45,068,284.16) than the other
observed countries in FY 2013.
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Table 4: Total Name Brand ARV
Expenditures from High Burden
Countries in FY 2012
Country
Angola
Congo, DRC
Côte d'Ivoire
Guyana
Haiti
Mozambique
Rwanda
South Africa
Tanzania
Uganda
Vietnam
Zambia
Zimbabwe
Total

Table 6: Total Name Brand ARV
Expenditures from High Burden
Countries in FY 2014

ARV Expenditures
$14,793.60
$3,698.40
$580,923.60
$2,493.62
$29,260.64
$1,150.80
$12,328.00
$273,711.92
$22,806.80
$444,287.29
$1,270,870.78
$69,653.20
$496,276.32
$3,222,254.97

Country
Burkina Faso
Burundi
Cameroon
Côte d'Ivoire
Guyana
Haiti
Mozambique
Nigeria
Rwanda
Senegal
South Africa
Uganda
Vietnam
Zambia
Zimbabwe
Total

Table 5: Total Name Brand ARV
Expenditures from High Burden
Countries in FY 2013
Country
Congo, DRC
Côte d'Ivoire
Dominican
Republic
Guyana
Haiti
Mozambique
Nigeria
Rwanda
South Africa
Tanzania
Uganda
Vietnam
Zambia
Zimbabwe
Total

ARV Expenditures
$171.25
$6,048.00
$6,660.00
$53,780.90
$23,107.44
$554,634.70
$1,552,459.00
$3,245,867.70
$88,470.88
$1,864.00
$75,568.80
$1,237,351.95
$2,851,679.00
$279,290.84
$995,732.56
$10,972,687.02

From FY 2012 to FY 2014, these SCMS

ARV Expenditures
$10,293.88
$2,058,297.18

partners spent $3,222,254.97,
$13,446,408.15, $10,972,687.02 on name-

$148,250.80
$66,329.92
$71,271.50
$1,066,103.80
$2,314,167.56
$286,559.88
$190,873.93
$1,482,592.34
$1,394,936.06
$2,598,901.00
$1,680,488.80
$77,341.50
$13,446,408.15

brand ARVs respectively for a total of
$27,641,350.14 over three years. In FY
2012 and FY 2013, Vietnam spent more
funds on name brand ARVs than the other
countries observed ($1,270,870.78 and
$2,598,901, respectively). Nigeria had the
highest expenditures for FY 2014 with
$3,245,867.70.
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Table 7: Total Name Brand Purchase
Orders from PEPFAR-Supported
Countries in FY 2012

Table 8: Total Name Brand Purchase
Orders from PEPFAR-Supported
Countries in FY 2013

Brand Name of
ARV
Aluvia
Epivir
Intelence
Isentress
Kaletra
Norvir
Prezista
Videx
Zerit
Ziagen
Total

Brand Name of
ARV
Aluvia
Crixivan
Epivir
Intelence
Invirase
Isentress
Kaletra
Norvir
Prezista
Reyataz
Videx
Viread
Zerit
Ziagen
Total

Number of
Purchase Orders
11
4
3
4
28
13
4
4
3
4
78

There were 78 name brand ARV
transactions in FY 2012. The most

Number of
Purchase Orders
49
1
5
5
1
6
37
17
8
7
4
1
1
2
144

frequently purchased name brand

In FY 2013, there were 144 name brand

medication was Keletra with a total of 28

ARV transactions. The most frequently

purchases.

purchased name brand medication was
Aluvia with a total of 49 purchases.

9

Table 9: Total Name Brand Purchase
Orders from PEPFAR-Supported
Countries in FY 2014

There were 164 name brand ARV

Brand Name
Number of
of ARV
Purchase Orders
Aluvia
29
Epivir
1
Intelence
17
Invirase
7
Isentress
26
Kaletra
32
Norvir
22
Prezista
19
Reyataz
10
Stocrin/Sustiva
1
Total
164

frequently purchased name brand

transactions in FY 2014. The most

medication was Keletra with a total of 32
purchases.

10

Chapter V
DISCUSSION
There are a few implications to the WHO’s recent recommendations to increase ART
to all HIV-affected individuals and the UNAIDS 90-90-90 goals. To meet these targets
established by UNAIDS and WHO, it is necessary to increase the volume of ARVs to the
affected countries and populations. The increase in ARVs would require a closer look at
how countries spend their allocated funds on ARV procurement to supply the target
populations adequately and efficiently.
From 2012 to 2013, the procurement of overall and generic ARVs increased,
however, from 2013 to 2014, there was a decrease in generic and overall ARV
procurement. The number of brand name ARV transactions increased during this three
year period from 78 in FY 2012, 144 in FY 2013, and 164 in FY 2014 respectively. The antiretroviral drug Keletra was the most frequently purchased ARV in FY 2012 and FY 2014. In
FY 2013, the most frequently purchased ARV was Aluvia.
One obstacle in obtaining generic ARVs is slow registration processes in a few
PEPFAR-funded countries (PEPFAR, 2009). Drugs that are distributed through the supply
chain must be registered with the FDA through PEPFAR. Once they are FDA approved or
even tentatively approved, drugs are then listed on the WHO website and/or submitted for
the WHO Prequalification Programme (FDA, 2015). WHO Prequalification Programme
ensure the quality of drugs and supplies for high burden diseases. This entire process can
take months or years to complete. If there is an extensive delay, countries are forced to use
the innovator drug, the product that was initially developed and typically sold at a higher
price, instead of the generic that is under the registration process.
11

Another obstacle is the ARV tender process. Country governments often discuss the
transactional processes and prices with the drug manufacturers far in advance to the
implementation of services. In most cases, countries may agree to multi-year contracts with
ARV drug manufacturers which reduce the flexibility in lowering ARV prices in the future
(Holmes et al., 2010).
Producing ARVs locally, instead of importing, may also be considered. One study
presented a case where two countries, Mozambique and Zimbabwe, implemented their
own pharmaceutical manufacturing sectors (Russo & Banda, 2015). Another study from
Tanzania found that locally produced drugs were found both in rural and urban areas,
while imported medicine was mostly found in urban areas (Mujinja et al., 2014). This
suggests that having local production may increase the availability of drugs in rural areas.
However, it is worth noting that these initiatives faced obstacles, such as human resources
deficiencies and unfavorable business environments (Russo & Banda, 2015). The current
challenge for these companies is ensuring the costs of production remain low in order to
compete with international manufacturers.
Although there are barriers to obtaining generic formulations for anti-retrovirals,
there is a dire consequence of low uptake of ARVs. If a high burden country is unable to
sustain or secure enough ARVs for HIV-affected individuals, it is unlikely that HIV/AIDS will
be eliminated in that location within the next several years, according to the WHO
recommendations.
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Chapter VI
CONCLUSION
It is also recommended that the international public health community continues to
explore solutions to overcome obstacles that prevent countries from securing generic
ARVs. Policy officials may consider revising the ARV registration process to decrease the
time between the initial drug submission, drug approval and drug distribution to the
country. High burden country governments may consider establishing shorter contracts
and negotiating the ARV tender processes annually, instead of every few years in order to
make adjustments to cheaper ARVs as needed. Countries may also invest in producing their
ARVs locally. In the implementation phase, this may require the support of non-profit or
international organizations to develop an efficient production system, but this effort may
have the potential to increase the number of ARVs in rural and urban regions over time.
As the quantity of treatment supplies increases, it will be necessary for international
partners to consider the burden on the countries and regions who may not have the
capacity for this unprecedented scale-up (Jamieson & Kellerman, 2016). It will also be
necessary to adjust the storage space, tracking methods and human resources to meet
these needs over time.
Integrating planning methods between the global supply chain managers,
partnering organizations and policy makers will be critical in achieving such ambitious
goals, such as the UNAIDS 90-90-90 targets and WHO recommendations. As researchers,
health staff and policy officials continue to work together to reduce the prevalence of HIV,
eventually the global community will be able to overcome this epidemic.
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Chapter VII
LIMITATIONS
Only SCMS data were considered, therefore the findings of this study cannot be
generalized and may only be applied to countries who receive support from SCMS and
PEPFAR. Also, the cost of shipping and international taxes were not considered in the total
expenditure calculation. Other costs associated with HIV treatment and supplies were not
applied to the final calculations. Lastly, the SCMS Delivery History Dataset lists the ARV
delivery date but does not label the fiscal year in which the funds originated. Therefore, it is
worth noting that the SCMS ARV expenditures indicated by fiscal year are estimates.
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